Alembic Pharma Receives USFDA Approval for Haloperidol Tablets Kumar Jeetendra | June 5, 2026 Alembic Pharmaceuticals Limited (Alembic) today announced that it has received final approval from the US Food & Drug Administration (USFDA) for its Abbreviated New Drug Application (ANDA) Haloperidol Tablets, USP, 1 mg, 2 mg, 5 mg, 10 mg, and 20 mg. The approved ANDA is therapeutically equivalent to the reference listed drug product (RLD), Haldol …
Micropipettes: Essential Tools for Scientific Innovation Kumar Jeetendra | June 22, 2026 Precision is key in laboratories, especially in modern science. Miscalculating a measurement can mean the difference between a treatment and no treatment. Micropipettes help with this precision. Micropipettes help transfer small volumes of liquid. From the lab to the pharmacy, these can help with research innovations. Micropipettes: Essential Tools Driving Precision and Innovation in Modern …
How BA/BE Studies Shape the Future of Generic Medicines Kumar Jeetendra | June 24, 2026 Generic medicines have become a cornerstone in healthcare as they allow healthcare systems to provide more affordable and accessible healthcare. Generic medicines must undergo significant scientific evaluations to ensure that they are as safe, high-quality, and therapeutically effective as the branded medications. Bioavailability (BA) and Bioequivalence (BE) studies are a key component in this scientific …
Innovation Without Limits: Advancing Pharma, Analytical Science & Laboratory Technologies Kumar Jeetendra | July 9, 2026 Innovation is central to the transformation of the pharmaceutical, analytical, and laboratory sectors. Organizations strive to harness the technologies of tomorrow in an effort to discover and develop operationally efficient methods to provide better solutions to patients. Challenges in global healthcare are more prevalent and complex. Innovation, in this case, is not a luxury, but …
Science in Motion:The Technologies Shaping Tomorrow’s Pharmaceutical Industry Kumar Jeetendra | July 9, 2026 The pharmaceutical sector is experiencing revolutionary changes for the first time in decades. Drug discovery, development, manufacturing, and delivery to patients in all corners of the globe is being altered due to the rapid pace of technologies, enhanced delivery and requests in healthcare, and the development of precision medicine. We are approaching 2026 and the …
Cipla Receives U.S. FDA Approval for Generic Advair Diskus® Kumar Jeetendra | July 28, 2026 Cipla Limited (BSE: 500087; NSE: CIPLA EQ; and hereafter referred to as “Cipla”) and its wholly owned subsidiary Cipla USA Inc., (hereafter referred to as “Cipla”), today announced that Cipla Limited has received U.S. Food and Drug Administration (FDA) approval for its Abbreviated New Drug Application (ANDA) for Generic Advair Diskus® (fluticasone propionate and salmeterol …
Mankind Pharma Enters CAR-T Therapy with Armed Cell Acquisition Kumar Jeetendra | October 17, 2026 As a part of its long term strategy to build a global innovation-led pharmaceutical business, Mankind Pharma (BSE: 543904 | NSE: MANKIND) through its subsidiary Mankind Pharma (Netherlands) B.V., has entered into a definitive agreement under which Mankind Pharma will acquire a majority stake in Armed Cell Therapeutics B.V., a Belgium-incorporated biotechnology company developing next-generation …
